EICHORCondition: Melanocortin Obesity Syndrome · MCOS · Sponsor: Icahn School of Medicine at Mount Sinai
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common cause of genetic obesity disorders. Atomoxetine was selected for this pilot trial because it has been shown to increase brain-derived neurotrophic factor (BDNF) within the central nervous system and in peripheral circulation. Targeting BDNF is a specific strategy for treating MC4R abnormalities because BDNF functions as a downstream mediator of MC4R signaling.
This description comes directly from the study's public registry record.
Joan C Han, MD · 212-241-3744 · joan.han@mountsinai.org
Always discuss trial participation with your own doctor first.
| Mount Sinai Hospital | New York, New York, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Not Yet Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06899178